| Platinum-Resistant Ovarian Carcinoma studied in …STUDIED_INderived109 of 109show fewer |
|---|
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07265739Phase 2 · not yet recruiting Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489287Phase 1 · recruiting GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04633239Phase 1 · recruiting Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081609Phase 1/Phase 2 · active not recruiting A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06964009Phase 1 · recruiting DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604766Phase 3 · recruiting An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585958Phase 1 · recruiting Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06515613Phase 1 · recruiting A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07755436Phase 1 · recruiting Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281471Phase 3 · recruiting Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05979298Phase 2 · completed Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06315491Phase 2 · terminated A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772882Phase 1 · not yet recruiting Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07470853Phase 1 · recruiting A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840589Phase 1 · suspended Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05225363Phase 1 · recruiting Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792552Phase 1 · recruiting A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06242470Phase 1 · recruiting A Study of MGC026 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07444814Phase 1 · recruiting Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02298959Phase 1 · active not recruiting Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113487Phase 2 · active not recruiting P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05465941Phase 2 · active not recruiting PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650986Phase 1/Phase 2 · active not recruiting Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226427Phase 1 · recruiting A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710288Phase 2 · recruiting A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07664735Phase 1 · not yet recruiting A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04055649Phase 2 · recruiting ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06321484Phase 1 · recruiting Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730347Phase 2 · recruiting A Study of Lorigerlimab in Participants With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03449108Phase 2 · active not recruiting LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05691504Phase 1 · active not recruiting Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05271318Phase 1/Phase 2 · active not recruiting Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05551507Phase 1/Phase 2 · recruiting IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06547840Phase 1 · recruiting A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05198804Phase 1/Phase 2 · completed A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05494580Phase 1/Phase 2 · completed Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07109414Phase 2/Phase 3 · active not recruiting Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01970722Phase 1 · active not recruiting Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04781088Phase 2 · active not recruiting Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756907Phase 1/Phase 2 · terminated Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06334432Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05483933Phase 1 · completed Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030907Phase 1 · recruiting A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04504916Phase 2 · terminated A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06264921Phase 1 · terminated A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870748Phase 2/Phase 3 · terminated REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05998135Phase 2 · recruiting Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04374630Phase 2 · completed Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05092360Phase 3 · terminated Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07117877Phase 2 · not yet recruiting Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07075250Phase 4 · not yet recruiting Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05274451Phase 1 · terminated A Study to Investigate LYL797 in Adults With Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891197terminated A Biomarker Screening Protocol for Participants With Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04019288Phase 1/Phase 2 · terminated AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672095Phase 1/Phase 2 · withdrawn Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03508570Phase 1 · completed Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973421Phase 2 · not yet recruiting Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03610490Phase 2 · terminated Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02641639Phase 2/Phase 3 · terminated FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03206047Phase 1/Phase 2 · completed Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03552471Phase 1 · completed Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05824975Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907527Phase 1 · active not recruiting Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691376Phase 1 · terminated Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06600841Phase 2 · not yet recruiting Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03949283Phase 3 · active not recruiting Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04787289Phase 2 · unknown A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06517433Phase 1 · completed First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06517485Phase 1 · completed First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05107739Phase 1 · terminated A Study of DeTIL-0255 in Adults With Advanced Malignancies · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03311334Phase 1/Phase 2 · terminated A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04718376Phase 1 · terminated A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03861403Phase 1 · terminated A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319628Phase 1/Phase 2 · active not recruiting First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04729608Phase 3 · terminated Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05295589Phase 2 · withdrawn Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04678102Phase 1 · unknown Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05736952Phase 2 · withdrawn Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898207Phase 1 · completed Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04753216Phase 2 · completed Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03398655Phase 3 · completed A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04851834Phase 1/Phase 2 · terminated NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05310344Phase 2 · unknown Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02889900Phase 2 · completed Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03542669Phase 1 · unknown Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05145218Phase 3 · unknown A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02028117Phase 1 · completed Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068974Phase 2 · unknown Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04376073Phase 2 · unknown Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02090582NA · completed H.O.P.E: Helping Ovarian Cancer Patients Cope · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01711970Phase 1/Phase 2 · completed A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02575807Phase 1/Phase 2 · terminated Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer · condition mapped ALIAS · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01653912Phase 1/Phase 2 · completed Dose-finding Study in Platinum-Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |